FDA panel votes in favor of Spark’s blindness gene therapy

Spark Therapeutics Inc's experimental gene therapy for a rare form of blindness improves vision and should be approved, advisers to the Food and Drug Administration concluded on Thursday, paving the way for the first U.S. gene therapy for an inherited disease.

• Source: cnbc
• 1,026
• October 17, 2017